Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk

ConclusionsOur findings provide the proof-of-concept of pharmacologically targeting ICMT in the treatment of glioblastoma via deactivation of Ras/Raf/Mek/Erk.

Source: Cancer Chemotherapy and Pharmacology - February 16, 2022 Category: Cancer & Oncology Source Type: research